![α-PD-1 therapy elevates Treg/Th balance and increases tumor cell pSmad3 that are both targeted by α-TGFβ antibody to promote durable rejection and immunity in squamous cell carcinomas | Journal for ImmunoTherapy of α-PD-1 therapy elevates Treg/Th balance and increases tumor cell pSmad3 that are both targeted by α-TGFβ antibody to promote durable rejection and immunity in squamous cell carcinomas | Journal for ImmunoTherapy of](https://media.springernature.com/lw685/springer-static/image/art%3A10.1186%2Fs40425-018-0493-9/MediaObjects/40425_2018_493_Fig6_HTML.png)
α-PD-1 therapy elevates Treg/Th balance and increases tumor cell pSmad3 that are both targeted by α-TGFβ antibody to promote durable rejection and immunity in squamous cell carcinomas | Journal for ImmunoTherapy of
PARP Targeted Alpha-Particle Therapy Enhances Response to PD-1 Immune-Checkpoint Blockade in a Syngeneic Mouse Model of Glioblastoma | ACS Pharmacology & Translational Science
![Engineering of α-PD-1 antibody-expressing long-lived plasma cells by CRISPR/Cas9-mediated targeted gene integration | Cell Death & Disease Engineering of α-PD-1 antibody-expressing long-lived plasma cells by CRISPR/Cas9-mediated targeted gene integration | Cell Death & Disease](https://media.springernature.com/full/springer-static/image/art%3A10.1038%2Fs41419-020-03187-1/MediaObjects/41419_2020_3187_Fig1_HTML.png)
Engineering of α-PD-1 antibody-expressing long-lived plasma cells by CRISPR/Cas9-mediated targeted gene integration | Cell Death & Disease
![Cancers | Free Full-Text | Harnessing Tumor Necrosis Factor Alpha to Achieve Effective Cancer Immunotherapy Cancers | Free Full-Text | Harnessing Tumor Necrosis Factor Alpha to Achieve Effective Cancer Immunotherapy](https://www.mdpi.com/cancers/cancers-13-00564/article_deploy/html/images/cancers-13-00564-g001.png)